Autobio Diagnostics Co Ltd - Asset Resilience Ratio
Autobio Diagnostics Co Ltd (603658) has an Asset Resilience Ratio of 2.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Autobio Diagnostics Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Autobio Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. See Autobio Diagnostics Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Autobio Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Autobio Diagnostics Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥268.45 Million | 2.29% |
| Total Liquid Assets | CN¥268.45 Million | 2.29% |
Asset Resilience Insights
- Limited Liquidity: Autobio Diagnostics Co Ltd maintains only 2.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Autobio Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio
Compare Autobio Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Autobio Diagnostics Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Autobio Diagnostics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.09% | CN¥3.57 Billion ≈ $522.93 Million |
CN¥11.88 Billion ≈ $1.74 Billion |
+3.83pp |
| 2023-12-31 | 26.26% | CN¥3.03 Billion ≈ $443.98 Million |
CN¥11.55 Billion ≈ $1.69 Billion |
+26.18pp |
| 2021-12-31 | 0.08% | CN¥7.34 Million ≈ $1.07 Million |
CN¥9.23 Billion ≈ $1.35 Billion |
-0.98pp |
| 2020-12-31 | 1.06% | CN¥85.89 Million ≈ $12.57 Million |
CN¥8.14 Billion ≈ $1.19 Billion |
-1.77pp |
| 2019-12-31 | 2.82% | CN¥120.16 Million ≈ $17.58 Million |
CN¥4.26 Billion ≈ $622.91 Million |
+2.79pp |
| 2018-12-31 | 0.04% | CN¥931.48K ≈ $136.30K |
CN¥2.66 Billion ≈ $388.74 Million |
-17.71pp |
| 2017-12-31 | 17.74% | CN¥388.09 Million ≈ $56.79 Million |
CN¥2.19 Billion ≈ $320.07 Million |
-25.78pp |
| 2016-12-31 | 43.53% | CN¥792.80 Million ≈ $116.01 Million |
CN¥1.82 Billion ≈ $266.53 Million |
-- |
About Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more